Inflammatory Bowel Diseases
Conditions
Keywords
fecal microbiota transplantation（FMT）, the Bai Nationality of Yunnan, Intestinal flora, colonoscope, transendoscopic enteral tubing（TET）, ulcerative colitis
Brief summary
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), affects over 2 million people worldwide . Although biological therapies have significantly improved the treatment outcomes for UC, nearly two-thirds of patients experience diminishing drug responses over time, making it crucial to explore novel therapeutic approaches targeting the underlying pathophysiology of UC. UC is associated with alterations in gut microbiota, reduced microbial diversity, and changes in the relative abundance of dominant bacterial populations. Specifically, UC patients exhibit a marked decrease in gut microbiota diversity at the species level, with a reduction in Firmicutes (e.g., Clostridium butyricum) and an increase in Actinobacteria, Proteobacteria (e.g., Escherichia coli), Enterobacteriaceae, Streptococcus, and Bacteroides . Given the association between gut microbiota alterations and IBD activity, several studies have proposed microbiota-based therapies, particularly fecal microbiota transplantation (FMT), as a treatment for UC.
Detailed description
FMT involves the infusion of fecal material from healthy donors into patients to restore gut microbiota balance. It is currently recognized as an effective treatment for recurrent or refractory Clostridium difficile infections. Numerous studies suggest that FMT, as a therapeutic tool to regulate gut microbial homeostasis, holds potential in treating UC and other diseases, although the biochemical and/or immune mechanisms underlying its effects remain unclear . Paramsothy et al. demonstrated the efficacy of autologous FMT compared to placebo, utilizing a protocol involving colonoscopy-guided FMT followed by daily enemas for 5 days per week over 8 weeks. However, the high financial burden of this approach limits its broader clinical application. Another study revealed that donor FMT prepared anaerobically for 1-week treatment led to a higher likelihood of remission at 8 weeks compared to autologous FMT. Further research is needed to assess its safety and maintain long-term remission rates. Our team's high-quality research findings indicate that the gut microbiota of populations in Yunnan's ethnic minority regions exhibits significantly higher diversity and regional specificity compared to urban populations. This has potential value in enhancing FMT efficacy. Previous studies revealed ethnic and regional differences in IBD prevalence in Yunnan Province, with lower rates among the Dai, Bai, and Miao ethnic groups compared to the Han population. An analysis of contributing factors highlighted the protective role of traditional ethnic diets, which increase gut microbial and viral diversity and probiotics content, thereby reducing UC prevalence. Based on this, the differences between donors in FMT may affect treatment outcomes, emphasizing the importance of identifying "high-quality" donors who maximize efficacy and minimize adverse reactions.
Interventions
PROCEDUREFecal microbiota transplantation
Transplantation of fresh fecal bacterial fluid into the ileocecum of patients with ulcerative colitis via the colonoscopic route
Sponsors
First Affiliated Hospital of Kunming Medical University
Chinese University of Hong Kong
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
14 Years to 79 Years
Healthy volunteers
No
Inclusion criteria
1. Age between 14 and 79 years (inclusive), any gender. 2. Diagnosed with ulcerative colitis (UC) per established clinical, endoscopic, and histological standards, with a disease duration of over 3 months. 3. Active mild-to-moderate UC, defined by a Mayo score of 4-10, including an endoscopic score ≥1 and a physician's global assessment score ≤2. 4. Stable baseline medication consisting of 5-aminosalicylic acid (mesalamine). 5. Signed written informed consent.
Exclusion criteria
1. Participants unable to provide informed consent, answer questionnaires, or supply samples. 2. Pregnant women or those attempting to conceive. 3. Participants unwilling to use effective contraception throughout the study. 4. Participants deemed in remission by investigators. 5. Evidence or history of toxic megacolon. 6. Isolated rectal inflammation (\<5 cm in extent). 7. Diagnosed with Crohn's disease or indeterminate colitis. 8. Participants with perianal diseases (e.g., fistulae, anal fissures). 9. History of significant gastrointestinal surgery (e.g., colectomy) ： * Minor surgeries will be reviewed case by case. * Patients with appendectomy within 3 months will be excluded. 10. Antibiotic use within the past 4 weeks for any reason, including for UC. 11. Steroid dependence requiring \>20 mg prednisone or \>9 mg budesonide daily at enrollment. 12. Recent or anticipated usage of prohibited drugs during the study period, including: * Rectal corticosteroids within 2 weeks prior to the first FMT. * Biologics (e.g., infliximab, adalimumab, vedolizumab) within 4 weeks prior to the first FMT. * Other major immunosuppressants (e.g., calcineurin inhibitors, antitumor drugs) within 12 weeks prior to treatment. * Probiotics within 4 weeks before the first FMT. * Experimental drugs or protocols within 12 weeks before the first FMT. * Anti-tuberculosis (TB or MAC) treatment within 4 weeks before the first FMT. Permitted Medications: Participants may continue using the following medications if doses are stable within specified timeframes before the first FMT: * Oral 5-aminosalicylic acid (stable for 4 weeks). * Azathioprine and methotrexate (≥90 days of use with stable doses for 4 weeks). * Oral prednisone (≤20 mg/day, stable for 2 weeks, gradually tapered at a rate of 2.5 mg/week to discontinue by week 8). Subjects should maintain the same doses of oral 5-aminosalicylates, thiopurines, and methotrexate during the study. For oral prednisolone, the dose had to be tapered off gradually, at a rate of 2.5mg per week, so that subjects were no longer exposed to steroids until week 8. Prohibited Medications: * Rectal corticosteroids (2 weeks before and throughout the study). * Antibiotics, antifungals, antivirals, probiotics, or prebiotics (4 weeks before and throughout the study). * Biologics or calcineurin inhibitors (12 weeks before and throughout the study). Participants using prohibited medications during the study will remain enrolled, and outcomes will still be evaluated. All prohibited medication usage will be recorded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| a Composite of Steroid-free Clinical Remission Together With Endoscopic Remission or Response | 12 weeks after fecal microbiota transplantation | total Mayo score of ≤2 points with no individual sub-score \>1 point, and at least a 1 point reduction from baseline in the endoscopy sub-score (MES). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Steroid-free Clinical Remission | 8 to 12 weeks after fecal microbiota transplantation | total Mayo score of ≤2 points with no individual sub-score \>1 point |
| Steroid-free Clinical Response | 8 to 12 weeks after fecal microbiota transplantation | reduction of 3 points or more on the Mayo score, a 50% or greater reduction from baseline in combined rectal bleeding plus stool frequency Mayo sub-scores, or both |
| Steroid-free Endoscopic Response | 8 to 12 weeks after fecal microbiota transplantation | Mayo endoscopy sub-score of 1 or less, with a reduction of at least 1 point from baseline |
| Changes in Microbial | 0、1、8、12 weeks after fecal microbiota transplantation | Variations in fecal microbiota composition, function, and metabolites within each group (Han donor group and Bai donor group) |
| Duration of Microbiota Recovery From Baseline Within Groups. | 0、1、8、12 weeks after fecal microbiota transplantation | Duration of microbiota recovery from baseline within groups. |
| Intergroup Differences in Recipients' Microbiota Composition Between the Han and Bai Donor Groups | 0、1、8、12 weeks after fecal microbiota transplantation | Intergroup differences in recipients' microbiota composition between the Han and Bai donor groups |
| Proportional Contributions of Recipient, Donor, or Mixed-origin Microbiota in FMT Recipients | 0、1、8、12 weeks after fecal microbiota transplantation | Proportional contributions of recipient, donor, or mixed-origin microbiota in FMT recipients |
| Dominant Bacterial Strains in Highly Effective Cases of FMT Treatment. | 0、1、8、12 weeks after fecal microbiota transplantation | Dominant bacterial strains in highly effective cases of FMT treatment. |
Countries
China
Contacts
PRINCIPAL_INVESTIGATORL Y Miao, Doctor
First Affiliated Hospital of Kunming Medical University
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 44.85 years |
| Race and Ethnicity Not Collected | 0 Participants |
| Sex: Female, Male Female | 13 Participants |
| Sex: Female, Male Male | 56 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 41 | 0 / 48 |
| other Total, other adverse events | 0 / 41 | 0 / 48 |
| serious Total, serious adverse events | 0 / 41 | 0 / 48 |
Outcome results
None listed